Opicapone in clinical practice (OPTIPARK)_V1
Research type
Research Study
Full title
Efficacy and safety of opicapone in clinical practice in Parkinson’s Disease patients with wearing-off motor fluctuations
IRAS ID
206501
Contact name
Andrew Lees
Contact email
Eudract number
2016-002391-27
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 9 months, 31 days
Research summary
The study plans to collect more information about how well and how safe a new medication called opicapone (OPC) is at treating Parkinson’s disease with wearing-off motor fluctuations. Wearing-off motor fluctuation is a complication in Parkinson's disease. During wearing-off, the symptoms of Parkinson's disease re-appear or worsen before the next dose of medication is due, and improves after the next dose of medication is taken. Participants will be invited to take part in the study if they have Parkinson’s Disease with wearing-off motor fluctuations and are currently being treated with a medication containing Levodopa. Participants will be on the study for 6 months and will have to take opicapone, every day as capsule, at least one hour before bed or after their last daily dose of Levodopa. The study will be run at NHS hospitals.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
16/EE/0357
Date of REC Opinion
7 Oct 2016
REC opinion
Further Information Favourable Opinion